1
|
Mandler M, Rockenstein E, Overk C, Mante M, Florio J, Adame A, Kim C, Santic R, Schneeberger A, Mattner F, Schmidhuber S, Galabova G, Spencer B, Masliah E, Rissman RA. Effects of single and combined immunotherapy approach targeting amyloid β protein and α-synuclein in a dementia with Lewy bodies-like model. Alzheimers Dement 2019; 15:1133-1148. [PMID: 31378574 DOI: 10.1016/j.jalz.2019.02.002] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2018] [Revised: 01/22/2019] [Accepted: 02/25/2019] [Indexed: 12/22/2022]
Abstract
INTRODUCTION Immunotherapeutic approaches targeting amyloid β (Aβ) protein and tau in Alzheimer's disease and α-synuclein (α-syn) in Parkinson's disease are being developed for treating dementia with Lewy bodies. However, it is unknown if single or combined immunotherapies targeting Aβ and/or α-syn may be effective. METHODS Amyloid precursor protein/α-syn tg mice were immunized with AFFITOPEs® (AFF) peptides specific to Aβ (AD02) or α-syn (PD-AFF1) and the combination. RESULTS AD02 more effectively reduced Aβ and pTau burden; however, the combination exhibited some additive effects. Both AD02 and PD-AFF1 effectively reduced α-syn, ameliorated degeneration of pyramidal neurons, and reduced neuroinflammation. PD-AFF1 more effectively ameliorated cholinergic and dopaminergic fiber loss; the combined immunization displayed additive effects. AD02 more effectively improved buried pellet test behavior, whereas PD-AFF1 more effectively improved horizontal beam test; the combined immunization displayed additive effects. DISCUSSION Specific active immunotherapy targeting Aβ and/or α-syn may be of potential interest for the treatment of dementia with Lewy bodies.
Collapse
Affiliation(s)
| | - Edward Rockenstein
- Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA
| | - Cassia Overk
- Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA
| | - Michael Mante
- Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA
| | - Jazmin Florio
- Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA
| | - Anthony Adame
- Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA
| | - Changyoun Kim
- Division of Neuroscience and Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, USA
| | | | | | | | | | | | - Brian Spencer
- Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA
| | - Eliezer Masliah
- Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA; Division of Neuroscience and Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, USA; Department of Pathology, University of California, San Diego, La Jolla, CA, USA
| | - Robert A Rissman
- Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA; VA San Diego Healthcare System, La Jolla, CA, USA.
| |
Collapse
|
10
|
Zimprich A, Müller-Myhsok B, Farrer M, Leitner P, Sharma M, Hulihan M, Lockhart P, Strongosky A, Kachergus J, Calne DB, Stoessl J, Uitti RJ, Pfeiffer RF, Trenkwalder C, Homann N, Ott E, Wenzel K, Asmus F, Hardy J, Wszolek Z, Gasser T. The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. Am J Hum Genet 2004; 74:11-9. [PMID: 14691730 PMCID: PMC1181898 DOI: 10.1086/380647] [Citation(s) in RCA: 159] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2003] [Accepted: 10/08/2003] [Indexed: 11/03/2022] Open
Abstract
Recently, a new locus (PARK8) for autosomal dominant parkinsonism has been identified in one large Japanese family. Linkage has been shown to a 16-cM centromeric region of chromosome 12, between markers D12S1631 and D12S339. We tested 21 white families with Parkinson disease and an inheritance pattern compatible with autosomal dominant transmission for linkage in this region. Criteria for inclusion were at least three affected individuals in more than one generation. A total of 29 markers were used to saturate the candidate region. One hundred sixty-seven family members were tested (84 affected and 83 unaffected). Under the assumption of heterogeneity and through use of an affecteds-only model, a maximum multipoint LOD score of 2.01 was achieved in the total sample, with an estimated proportion of families with linkage of 0.32. This LOD score is significant for linkage in a replication study and corresponds to a P value of.0047. Two families (family A [German Canadian] and family D [from western Nebraska]) reached significant linkage on their own, with a combined maximum multipoint LOD score of 3.33, calculated with an affecteds-only model (family A: LOD score 1.67, P=.0028; family D: LOD score 1.67, P=.0028). When a penetrance-dependent model was calculated, the combined multipoint LOD score achieved was 3.92 (family A: LOD score 1.68, P=.0027; family D: LOD score 2.24, P=.0007). On the basis of the multipoint analysis for the combined families A and D, the 1-LOD support interval suggests that the most likely disease location is between a CA repeat polymorphism on genomic clone AC025253 (44.5 Mb) and marker D12S1701 (47.7 Mb). Our data provide evidence that the PARK8 locus is responsible for the disease in a subset of families of white ancestry with autosomal dominant parkinsonism, suggesting that it could be a more common locus.
Collapse
Affiliation(s)
- Alexander Zimprich
- Hertie-Institute for Clinical Brain Research, Department for Neurodegenerative Diseases, University of Tuebingen, Tuebingen, Germany; Max-Planck-Institute of Psychiatry, Munich; Departments of Neurology and Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL; The Pacific Parkinson’s Research Centre, University Hospital and Department of Neurology, University of British Columbia, Vancouver; Department of Neurology, University of Tennessee Health Science Center, Memphis; Department of Clinical Neurophysiology, University of Goettingen, Goettingen, Germany; Department of Neurology, University Hospital Graz, Karl-Franzens-University, Graz, Austria; and Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda
| | - Bertram Müller-Myhsok
- Hertie-Institute for Clinical Brain Research, Department for Neurodegenerative Diseases, University of Tuebingen, Tuebingen, Germany; Max-Planck-Institute of Psychiatry, Munich; Departments of Neurology and Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL; The Pacific Parkinson’s Research Centre, University Hospital and Department of Neurology, University of British Columbia, Vancouver; Department of Neurology, University of Tennessee Health Science Center, Memphis; Department of Clinical Neurophysiology, University of Goettingen, Goettingen, Germany; Department of Neurology, University Hospital Graz, Karl-Franzens-University, Graz, Austria; and Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda
| | - Matthew Farrer
- Hertie-Institute for Clinical Brain Research, Department for Neurodegenerative Diseases, University of Tuebingen, Tuebingen, Germany; Max-Planck-Institute of Psychiatry, Munich; Departments of Neurology and Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL; The Pacific Parkinson’s Research Centre, University Hospital and Department of Neurology, University of British Columbia, Vancouver; Department of Neurology, University of Tennessee Health Science Center, Memphis; Department of Clinical Neurophysiology, University of Goettingen, Goettingen, Germany; Department of Neurology, University Hospital Graz, Karl-Franzens-University, Graz, Austria; and Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda
| | - Petra Leitner
- Hertie-Institute for Clinical Brain Research, Department for Neurodegenerative Diseases, University of Tuebingen, Tuebingen, Germany; Max-Planck-Institute of Psychiatry, Munich; Departments of Neurology and Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL; The Pacific Parkinson’s Research Centre, University Hospital and Department of Neurology, University of British Columbia, Vancouver; Department of Neurology, University of Tennessee Health Science Center, Memphis; Department of Clinical Neurophysiology, University of Goettingen, Goettingen, Germany; Department of Neurology, University Hospital Graz, Karl-Franzens-University, Graz, Austria; and Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda
| | - Manu Sharma
- Hertie-Institute for Clinical Brain Research, Department for Neurodegenerative Diseases, University of Tuebingen, Tuebingen, Germany; Max-Planck-Institute of Psychiatry, Munich; Departments of Neurology and Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL; The Pacific Parkinson’s Research Centre, University Hospital and Department of Neurology, University of British Columbia, Vancouver; Department of Neurology, University of Tennessee Health Science Center, Memphis; Department of Clinical Neurophysiology, University of Goettingen, Goettingen, Germany; Department of Neurology, University Hospital Graz, Karl-Franzens-University, Graz, Austria; and Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda
| | - Mary Hulihan
- Hertie-Institute for Clinical Brain Research, Department for Neurodegenerative Diseases, University of Tuebingen, Tuebingen, Germany; Max-Planck-Institute of Psychiatry, Munich; Departments of Neurology and Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL; The Pacific Parkinson’s Research Centre, University Hospital and Department of Neurology, University of British Columbia, Vancouver; Department of Neurology, University of Tennessee Health Science Center, Memphis; Department of Clinical Neurophysiology, University of Goettingen, Goettingen, Germany; Department of Neurology, University Hospital Graz, Karl-Franzens-University, Graz, Austria; and Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda
| | - Paul Lockhart
- Hertie-Institute for Clinical Brain Research, Department for Neurodegenerative Diseases, University of Tuebingen, Tuebingen, Germany; Max-Planck-Institute of Psychiatry, Munich; Departments of Neurology and Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL; The Pacific Parkinson’s Research Centre, University Hospital and Department of Neurology, University of British Columbia, Vancouver; Department of Neurology, University of Tennessee Health Science Center, Memphis; Department of Clinical Neurophysiology, University of Goettingen, Goettingen, Germany; Department of Neurology, University Hospital Graz, Karl-Franzens-University, Graz, Austria; and Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda
| | - Audrey Strongosky
- Hertie-Institute for Clinical Brain Research, Department for Neurodegenerative Diseases, University of Tuebingen, Tuebingen, Germany; Max-Planck-Institute of Psychiatry, Munich; Departments of Neurology and Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL; The Pacific Parkinson’s Research Centre, University Hospital and Department of Neurology, University of British Columbia, Vancouver; Department of Neurology, University of Tennessee Health Science Center, Memphis; Department of Clinical Neurophysiology, University of Goettingen, Goettingen, Germany; Department of Neurology, University Hospital Graz, Karl-Franzens-University, Graz, Austria; and Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda
| | - Jennifer Kachergus
- Hertie-Institute for Clinical Brain Research, Department for Neurodegenerative Diseases, University of Tuebingen, Tuebingen, Germany; Max-Planck-Institute of Psychiatry, Munich; Departments of Neurology and Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL; The Pacific Parkinson’s Research Centre, University Hospital and Department of Neurology, University of British Columbia, Vancouver; Department of Neurology, University of Tennessee Health Science Center, Memphis; Department of Clinical Neurophysiology, University of Goettingen, Goettingen, Germany; Department of Neurology, University Hospital Graz, Karl-Franzens-University, Graz, Austria; and Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda
| | - Donald B. Calne
- Hertie-Institute for Clinical Brain Research, Department for Neurodegenerative Diseases, University of Tuebingen, Tuebingen, Germany; Max-Planck-Institute of Psychiatry, Munich; Departments of Neurology and Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL; The Pacific Parkinson’s Research Centre, University Hospital and Department of Neurology, University of British Columbia, Vancouver; Department of Neurology, University of Tennessee Health Science Center, Memphis; Department of Clinical Neurophysiology, University of Goettingen, Goettingen, Germany; Department of Neurology, University Hospital Graz, Karl-Franzens-University, Graz, Austria; and Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda
| | - Jon Stoessl
- Hertie-Institute for Clinical Brain Research, Department for Neurodegenerative Diseases, University of Tuebingen, Tuebingen, Germany; Max-Planck-Institute of Psychiatry, Munich; Departments of Neurology and Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL; The Pacific Parkinson’s Research Centre, University Hospital and Department of Neurology, University of British Columbia, Vancouver; Department of Neurology, University of Tennessee Health Science Center, Memphis; Department of Clinical Neurophysiology, University of Goettingen, Goettingen, Germany; Department of Neurology, University Hospital Graz, Karl-Franzens-University, Graz, Austria; and Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda
| | - Ryan J. Uitti
- Hertie-Institute for Clinical Brain Research, Department for Neurodegenerative Diseases, University of Tuebingen, Tuebingen, Germany; Max-Planck-Institute of Psychiatry, Munich; Departments of Neurology and Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL; The Pacific Parkinson’s Research Centre, University Hospital and Department of Neurology, University of British Columbia, Vancouver; Department of Neurology, University of Tennessee Health Science Center, Memphis; Department of Clinical Neurophysiology, University of Goettingen, Goettingen, Germany; Department of Neurology, University Hospital Graz, Karl-Franzens-University, Graz, Austria; and Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda
| | - Ronald F. Pfeiffer
- Hertie-Institute for Clinical Brain Research, Department for Neurodegenerative Diseases, University of Tuebingen, Tuebingen, Germany; Max-Planck-Institute of Psychiatry, Munich; Departments of Neurology and Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL; The Pacific Parkinson’s Research Centre, University Hospital and Department of Neurology, University of British Columbia, Vancouver; Department of Neurology, University of Tennessee Health Science Center, Memphis; Department of Clinical Neurophysiology, University of Goettingen, Goettingen, Germany; Department of Neurology, University Hospital Graz, Karl-Franzens-University, Graz, Austria; and Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda
| | - Claudia Trenkwalder
- Hertie-Institute for Clinical Brain Research, Department for Neurodegenerative Diseases, University of Tuebingen, Tuebingen, Germany; Max-Planck-Institute of Psychiatry, Munich; Departments of Neurology and Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL; The Pacific Parkinson’s Research Centre, University Hospital and Department of Neurology, University of British Columbia, Vancouver; Department of Neurology, University of Tennessee Health Science Center, Memphis; Department of Clinical Neurophysiology, University of Goettingen, Goettingen, Germany; Department of Neurology, University Hospital Graz, Karl-Franzens-University, Graz, Austria; and Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda
| | - Nikolaus Homann
- Hertie-Institute for Clinical Brain Research, Department for Neurodegenerative Diseases, University of Tuebingen, Tuebingen, Germany; Max-Planck-Institute of Psychiatry, Munich; Departments of Neurology and Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL; The Pacific Parkinson’s Research Centre, University Hospital and Department of Neurology, University of British Columbia, Vancouver; Department of Neurology, University of Tennessee Health Science Center, Memphis; Department of Clinical Neurophysiology, University of Goettingen, Goettingen, Germany; Department of Neurology, University Hospital Graz, Karl-Franzens-University, Graz, Austria; and Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda
| | - Erwin Ott
- Hertie-Institute for Clinical Brain Research, Department for Neurodegenerative Diseases, University of Tuebingen, Tuebingen, Germany; Max-Planck-Institute of Psychiatry, Munich; Departments of Neurology and Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL; The Pacific Parkinson’s Research Centre, University Hospital and Department of Neurology, University of British Columbia, Vancouver; Department of Neurology, University of Tennessee Health Science Center, Memphis; Department of Clinical Neurophysiology, University of Goettingen, Goettingen, Germany; Department of Neurology, University Hospital Graz, Karl-Franzens-University, Graz, Austria; and Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda
| | - Karoline Wenzel
- Hertie-Institute for Clinical Brain Research, Department for Neurodegenerative Diseases, University of Tuebingen, Tuebingen, Germany; Max-Planck-Institute of Psychiatry, Munich; Departments of Neurology and Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL; The Pacific Parkinson’s Research Centre, University Hospital and Department of Neurology, University of British Columbia, Vancouver; Department of Neurology, University of Tennessee Health Science Center, Memphis; Department of Clinical Neurophysiology, University of Goettingen, Goettingen, Germany; Department of Neurology, University Hospital Graz, Karl-Franzens-University, Graz, Austria; and Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda
| | - Friedrich Asmus
- Hertie-Institute for Clinical Brain Research, Department for Neurodegenerative Diseases, University of Tuebingen, Tuebingen, Germany; Max-Planck-Institute of Psychiatry, Munich; Departments of Neurology and Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL; The Pacific Parkinson’s Research Centre, University Hospital and Department of Neurology, University of British Columbia, Vancouver; Department of Neurology, University of Tennessee Health Science Center, Memphis; Department of Clinical Neurophysiology, University of Goettingen, Goettingen, Germany; Department of Neurology, University Hospital Graz, Karl-Franzens-University, Graz, Austria; and Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda
| | - John Hardy
- Hertie-Institute for Clinical Brain Research, Department for Neurodegenerative Diseases, University of Tuebingen, Tuebingen, Germany; Max-Planck-Institute of Psychiatry, Munich; Departments of Neurology and Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL; The Pacific Parkinson’s Research Centre, University Hospital and Department of Neurology, University of British Columbia, Vancouver; Department of Neurology, University of Tennessee Health Science Center, Memphis; Department of Clinical Neurophysiology, University of Goettingen, Goettingen, Germany; Department of Neurology, University Hospital Graz, Karl-Franzens-University, Graz, Austria; and Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda
| | - Zbigniew Wszolek
- Hertie-Institute for Clinical Brain Research, Department for Neurodegenerative Diseases, University of Tuebingen, Tuebingen, Germany; Max-Planck-Institute of Psychiatry, Munich; Departments of Neurology and Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL; The Pacific Parkinson’s Research Centre, University Hospital and Department of Neurology, University of British Columbia, Vancouver; Department of Neurology, University of Tennessee Health Science Center, Memphis; Department of Clinical Neurophysiology, University of Goettingen, Goettingen, Germany; Department of Neurology, University Hospital Graz, Karl-Franzens-University, Graz, Austria; and Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda
| | - Thomas Gasser
- Hertie-Institute for Clinical Brain Research, Department for Neurodegenerative Diseases, University of Tuebingen, Tuebingen, Germany; Max-Planck-Institute of Psychiatry, Munich; Departments of Neurology and Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL; The Pacific Parkinson’s Research Centre, University Hospital and Department of Neurology, University of British Columbia, Vancouver; Department of Neurology, University of Tennessee Health Science Center, Memphis; Department of Clinical Neurophysiology, University of Goettingen, Goettingen, Germany; Department of Neurology, University Hospital Graz, Karl-Franzens-University, Graz, Austria; and Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda
| |
Collapse
|